Exscientia (NASDAQ:EXAI) Trading Down 5.3% - Should You Sell?

Shares of Exscientia plc (NASDAQ:EXAI - Get Free Report) fell 5.3% during trading on Friday . The stock traded as low as $5.01 and last traded at $5.03. 147,384 shares were traded during mid-day trading, a decline of 77% from the average session volume of 640,736 shares. The stock had previously closed at $5.31.

Analysts Set New Price Targets

EXAI has been the topic of several analyst reports. Barclays reaffirmed an "equal weight" rating and issued a $5.00 target price on shares of Exscientia in a report on Tuesday, August 13th. TD Cowen reissued a "hold" rating on shares of Exscientia in a report on Friday, August 9th.

Exscientia Stock Performance

The stock's 50 day moving average price is $5.04 and its 200 day moving average price is $5.15. The company has a current ratio of 4.54, a quick ratio of 5.93 and a debt-to-equity ratio of 0.06. The company has a market cap of $595.71 million, a price-to-earnings ratio of -3.11 and a beta of 0.83.

Exscientia (NASDAQ:EXAI - Get Free Report) last announced its quarterly earnings data on Thursday, August 15th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.05). The company had revenue of $5.60 million for the quarter. Exscientia had a negative net margin of 882.09% and a negative return on equity of 49.10%. On average, analysts expect that Exscientia plc will post -1.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Exscientia

Several hedge funds and other institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. lifted its position in Exscientia by 66.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,576 shares of the company's stock valued at $47,000 after buying an additional 3,821 shares in the last quarter. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Exscientia during the 2nd quarter valued at $54,000. International Assets Investment Management LLC purchased a new stake in Exscientia during the 3rd quarter worth $77,000. XTX Topco Ltd acquired a new stake in Exscientia in the 3rd quarter valued at $82,000. Finally, Federated Hermes Inc. purchased a new position in Exscientia in the second quarter valued at about $115,000. 41.58% of the stock is owned by institutional investors and hedge funds.

Exscientia Company Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.